Feature | January 21, 2015

ACC 2015 Late Breaking Clinical Trials

ACC 2015 late breaking trials
The late-breaking clinical trials at the American College of Cardiology (ACC) 2015 annual meeting will include the latest data on outcomes for transcatheter aortic valve repair (TAVR), transcatheter mitral valve repair (TMRV), the use of computed tomography (CT) angiography to evaluate chest pain, first report on the use of TAVR embolic protection, denervation for pulmonary arterial hypertension, new antiplatelet/anticoagulation therapies and outcomes with drug-eluting stents versus bypass surgery. 
 
ACC.15 will include five late-breaking clinical trial sessions and two featured clinical research sessions. There will be a late-breaking clinical trial deep dive session, where attendees can find out what it all means.
 
ACC.15 Opening Showcase and the Joint ACC/JACC Late-Breaking Clinical Trials
Session 400
Saturday, March 14, 8 – 10 a.m.
ACC.15 Main Tent (Hall H)
 
 
 
 
Joint American College of Cardiology/Journal of the American Medical Association Late-Breaking Clinical Trials
Session 402
Sunday, March 15, 8 – 9:15 a.m.
ACC.15 Main Tent (Hall H)
 
Effect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes (OSLER-1 and -2)
 
• The EMBRACE STEMI Study: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Efficacy of Intravenous Bendavia on Reperfusion Injury in Patients Treated with Standard Therapy Including Primary PCI and Stenting for ST-segment Elevation Myocardial Infarction (EMBRACE STEMI)
 
 
 
Economic Comparison of Anatomic Versus Functional Diagnostic Testing Strategies in Symptomatic Patients with Suspected CAD: Results from the PROspective Multicenter Imaging Study for Evaluation of chest pain (PROMISE) Trial
 
Late-Breaking Clinical Trials III
Session 404
Sunday, March 15, 10:45 a.m. – noon
ACC.15 Main Tent (Hall H)
 
 
 
 
 
 
 
Featured Clinical Research Session I
Session 406
Sunday, March 15, 12:30 – 1:45 p.m.
Room 9
 
 
Ulnar Artery Intervention Non-inferior To Radial Approach: A Reality Or Myth. AJmer ULnar ARtery (AJULAR) Working Group Study 
 
• Long-Term Outcomes After Stenting Versus Coronary Artery Bypass Grafting for Unprotected Left Main Coronary Artery Disease: 5-Year Results of the PRECOMBAT Study
 
• Dual-antiplatelet Therapy Beyond One Year in Patients Receiving Coronary Stents For Treatment of Acute Coronary Syndrome: Analysis from the Dual Antiplatelet Therapy Study
 
• Perioperative Results And Complications in 15,964 Transcatheter Aortic Valve Implantations From The German Gary Registry
 
 
Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trials
Session 408
Monday, March 16, 8 – 9:15 a.m.
ACC.15 Main Tent (Hall H)
 
Ablation vs. Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted device: Results from the AATAC Multicenter Randomized Trial
 
Effectiveness of Surgical Ablation of Atrial Fibrillation during Mitral Valve Surgery: A Randomized Clinical Trial from the Cardiothoracic Surgical Trials Network
 
• Long-Term Effect of Goal Directed Weight Management on an Atrial Fibrillation Cohort: A 5-Year Follow-Up Study (LEGACY Study)
 
• Everolimus-Eluting Stents versus Bypass Surgery for Multivessel Coronary Artery Disease (BEST)
 
• Effect of Remote Ischemic Preconditioning on Clinical Outcomes in Patients Undergoing Coronary Artery Bypass Graft Surgery: A Multi-Center Randomized Controlled Clinical Trial (ERRICA)
 
 
Late-Breaking Clinical Trials V: [email protected] Interventional Cardiology
Session 410
Monday, March 16, 10:45 a.m. – noon
ACC.15 Main Tent (Hall H)
 
• The Total Trial: A Randomized Trial Of Routine Aspiration Thrombectomy With Percutaneous Coronary Intervention (PCI) Versus PCI Alone In Patients With St-elevation Myocardial Infarction Undergoing Primary PCI
 
Transradial Versus Transfemoral Access In Patients With Acute Coronary Syndromes Undergoing Invasive Management: Results From The Minimizing Adverse Haemorrhagic Events By Transradial Access Site And Systemic Implementation Of Angiox (matrix) Access Site Program
 
Bivalirudin Infusion Compared to Unfractionated Heparin In Patients With Acute Coronary Syndromes Undergoing Invasive Management: Results From The Minimizing Adverse Haemorrhagic Events By Transradial Access Site And Systemic Implementation Of Angiox (matrix) Anti-thrombin Program
 
• The Third DANish Study of Optimal Acute Treatment of Patients with ST-segment Elevation Myocardial Infarction: PRImary PCI in MULTIvessel Disease
 
After Eighty Study
 
 
LBCT Deep Dive
Session 412
Monday, March 16, 12:30 – 1:45 p.m.
ACC.15 Main Tent (Hall H)
 
• Hear key highlights of the late-breaker clinical trials presented throughout ACC.15 and learn about what it means for physicians and their patients.
 
Featured Clinical Research Session II
Session 414
Monday, March 16, 12:30 – 1:45 p.m.
Room 6E
 
• Reduction in Total (First and Recurrent) Cardiovascular Events with Ezetimibe/Simvastatin Compared with Simvastatin Alone post Acute Coronary Syndromes in the IMPROVE-IT Trial
 
• A Prospective Comparison of Algisyl-LVR with Standard Medical Therapy to Determine Impact on Functional Capacity and Clinical Outcomes in Patients with Advanced Heart Failure (AUGMENT-HF Trial)
 
Effects of Selective Serotonin Re-Uptake Inhibition on Mortality, Morbidity and Mood in Depressed Heart Failure Patients
 
Baroreflex Activation Therapy for the Treatment of Heart Failure with a Reduced Ejection Fraction
 
Pulmonary Artery Denervation For Treatment Of Pulmonary Arterial Hypertension: Results from a controlled before and after study
 
For more information: http://accscientificsession.acc.org/ACC.aspx 
 

Related Content

Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
Overlay Init